Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VBC101 in Advanced Solid Tumor Malignancies
NCT07136779Phase 2Recruiting
- Sponsor
- VelaVigo
- Start
- Sep 2025
- Primary completion
- Jul 2027
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of VBC101 in solid tumor, sponsored by VelaVigo. Started Sep 2025; status: recruiting.
02
Drugs
VBC101
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07136779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07136779.